Allan Gelber, MD, PhD, MPHProfessor of Medicine Deputy Director for Education and Faculty Development, Division of RheumatologyAssociate Faculty, Welch Center for Prevention, Epidemiology & Clinical Research
- M.D.: Johns Hopkins University School of Medicine, Baltimore MD
- Ph.D.: Johns Hopkins University Bloomberg School of Public Health, Clinical Investigation
- M.P.H.: Johns Hopkins University Bloomberg School of Public Health, Health Policy and Management
- Internship and Residency: Duke University Medical Center
- Post–doctoral Fellowship: Johns Hopkins University School of Medicine, Rheumatology
Dr. Allan Gelber is Professor of Medicine and Deputy Director for Education and Faculty Development in the Division of Rheumatology. He holds a joint appointment in the Department of Epidemiology at the Bloomberg School of Public Health and is Associate Faculty at the Welch Center for Prevention, Epidemiology and Clinical Research. Dr. Gelber is a graduate of the Johns Hopkins University School of Medicine and received both his MPH and PhD degrees (the latter in Clinical Investigation) at the Bloomberg School. He pursued internship and residency training in internal medicine at Duke University and then undertook his fellowship training in rheumatology at Johns Hopkins.
Dr. Gelber has had an active role as an Educator in the Rheumatic Diseases. He previously served as Fellowship Program Director at Johns Hopkins from 2001-2011. He has subsequently shifted his primary educational focus from rheumatology fellows to medical students, as well as to internal medicine housestaff on the Bayview and Johns Hopkins campuses. He directs the Musculoskeletal Section of the Genes-to-Society Course to 2nd year medical students at Johns Hopkins.
In addition, Dr. Gelber’s research activity applies the tools of clinical epidemiology across the spectrum of rheumatic disorders. His investigative pursuits include recent studies identifying predictors of prevalent and incident gout, autoantibodies in primary and secondary Sjogren’s syndrome, predictors of outcomes in scleroderma, and cardiovascular disease burden and risk in rheumatoid arthritis.